Kokot F, Wiecek A, Grzeszczak W, Klin M
Department of Nephrology, Silesian School of Medicine, Katowice, Poland.
Miner Electrolyte Metab. 1990;16(1):25-9.
In 5 haemodialyzed patients the influence of 3 months' erythropoietin (EPO) treatment on plasma renin activity (PRA), aldosterone (Ald), vasopressin (AVP) and atrial natriuretic peptide (ANP) was studied. Results were compared with those obtained in 7 uraemic patients showing a similar haematocrit value as patients after EPO therapy and with those obtained in 10 healthy subjects. EPO treatment did not influence significantly blood pressure but was suppressing PRA and plasma Ald levels, and raising plasma ANP concentrations. EPO treatment was without influence on AVP plasma levels. Data obtained in this study suggest that EPO-induced endocrine alterations are not due to increased blood volume and only partially related to improvement of uraemic anaemia.
研究了促红细胞生成素(EPO)3个月治疗对5例血液透析患者血浆肾素活性(PRA)、醛固酮(Ald)、血管加压素(AVP)和心钠素(ANP)的影响。将结果与7例血细胞比容值与EPO治疗后患者相似的尿毒症患者以及10例健康受试者的结果进行比较。EPO治疗对血压无显著影响,但可抑制PRA和血浆Ald水平,并提高血浆ANP浓度。EPO治疗对AVP血浆水平无影响。本研究获得的数据表明,EPO诱导的内分泌改变并非由于血容量增加,且仅部分与尿毒症贫血的改善有关。